6,266
Views
5
CrossRef citations to date
0
Altmetric
Drug Evaluation

Onasemnogene abeparvovec for the treatment of spinal muscular atrophy

ORCID Icon, , , , & ORCID Icon
Pages 1075-1090 | Received 12 Jan 2022, Accepted 12 Apr 2022, Published online: 02 May 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Martin Donnelley, David Parsons & Ivanka Prichard. (2023) Perceptions of airway gene therapy for cystic fibrosis. Expert Opinion on Biological Therapy 23:1, pages 103-113.
Read now

Articles from other publishers (4)

Jianli Sun. (2023) Editorial: Advances in spinal muscular atrophy. Frontiers in Cellular Neuroscience 17.
Crossref
Georg M. Stettner, Oswald Hasselmann, Anne Tscherter, Elea Galiart, David Jacquier & Andrea Klein. (2023) Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study. BMC Neurology 23:1.
Crossref
Kyeong Yeol Kim, Chan Woong Jang, Seok Young Chung, Myungsang Kim, Sung-Rae Cho & Han Eol Cho. (2023) Usefulness of YouTube in Sharing Information about New Gene Therapy for Spinal Muscular Atrophy: A Content Analysis. Healthcare 11:1, pages 147.
Crossref
V Vinay, SushilKumar Munjal, MN Dinesh Kanna, Sandeep Jain, Paras Verma & M Arunachalam. (2023) Respiratory failure in spinal muscular atrophy: A case report and review of literature. Journal of Primary Care Specialties 4:1, pages 28.
Crossref